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Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) that is commonly used for 
arthritis, gout, and other musculoskeletal disorders. Piroxicam is poorly soluble in water and according 
to the biopharmaceutical drug classification system (BCS) is classified as a Class II drug with good 
permeability but poor dissolution. The self-nanoemulsifying drug delivery system (SNEDDS) has been 
extensively employed to improve the dissolution and absorption of water-insoluble drugs within the 
gastrointestinal tract, leading to enhanced oral bioavailability and increased therapeutic effect of the 
loaded drugs. Therefore, the present study aims to evaluate the anti-inflammatory activity of 
piroxicam-loaded SNEDDS as compared to conventional piroxicam suspension that was observed in 
male Wistar strain rats. The SNEDDS was tailored from a mixture of oleic acid, tween 80, and 
propylene glycol. Twenty male Wistar strain rats (aged 2-3 months, weighed 150-250g) were selected 
and were divided equally into 4 different groups receiving 1% PVP, SNEDDS carrier, piroxicam 
suspension (1.8 mg/kg BW), and SNEDDS piroxicam (1.8 mg/kg BW). Acute inflammation was 
induced by a carrageenan-induced paw edema model where the carrageenan was injected sub plantar 
in the hind paw of the rats to induce edema. Several parameters including paw edema volume, AUC0-6, 
and percent anti-inflammatory effect, were measured to evaluate the anti-inflammatory activity 
experienced in each group. At the end of this study, the piroxicam SNEDDS group significantly 
demonstrated better protection from paw edema compared to the piroxicam suspension group 
(ρ<0.05), suggesting that SNEDDS may enhance the anti-inflammatory activity of piroxicam. 
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Even though various novel routes of administrations of drugs have been recently developed, yet 
oral administration is still predominantly preferred by most patients when taking drugs. About 40% of 
new drugs, however, suffer from poor water solubility that leads to poor drug absorption and 
ultimately poor oral bioavailability. This issue is observed mainly in the lipophilic drugs group 
including piroxicam (Obitte et al., 2013; Yang et al., 2016).  
Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam group that has been 
widely used for various musculoskeletal disorders such as osteoarthritis, rheumatoid arthritis, and 
gout, thanks to its anti-inflammatory effect by blocking cyclooxygenase. According to the 
Biopharmaceutical Drug Classification System (BCS), piroxicam is classified as a Class II drug which 
attributes to low solubility and high permeability (Motawea et al., 2017). This condition is not ideal for 
orally administered drugs as poor solubility will ultimately affect the therapeutic effect exerted by the 
drug. Since dissolution is a rate-limiting step, designing a proper oral drug formulation that focuses on 
enhancing absorption and bioavailability is demanded (Yang et al., 2016). Many attempts have been 
employed to solve this problem including microemulsion (Abd-Allah et al., 2010), nanostructured 
lipid carrier (Otarola et al., 2015), solid dispersion (Barzegar-Jalali et al., 2014; Hussain et al., 2019), 
and lipid formulation (Jannin et al., 2015), yet further investigations are still needed for these 
approaches before clinical application.  
A self-nanoemulsifying drug delivery system (SNEDDS) is an advanced technology of lipid-
based drug delivery system to overcome drugs with inherent problems of low solubility and poor oral 
absorption (Buya et al., 2020). SNEDDS comprises oil, surfactant, and co-surfactant that form a 
translucent, anhydrous isotropic mixture. SNEDDS is a thermodynamically stable formulation that can 
spontaneously emulsify into fine oil-in-water nanoemulsions when exposed to the aqueous 
environment of the gastrointestinal tract (GIT) facilitated by gentle agitation of the digestive motility 
(Cherniakov et al., 2015; Rehman et al., 2017).  
Recent studies suggest SNEDDS may enhance solubility (Ke et al., 2016) and oral 
bioavailability (Baloch et al., 2019; Mohsin et al., 2016) of drug targets as well as improve the 
therapeutic effect (Hapsari et al., 2016) of drugs of interest. Such findings and, not to mention, its 
relatively high solubilization capacity for lipophilic drugs (Cherniakov et al., 2015) and its feature to 
produce nanometric-sized emulsion droplets (usually below 200 nm) (Rehman et al., 2017), SNEDDS 
is likely an ideal approach for improving solubility, bioavailability, and pharmacological effect of 
piroxicam. Therefore, this study aims to evaluate the anti-inflammatory activity of piroxicam-loaded 
SNEDDS compared to conventional piroxicam suspension. The composition of SNEDDS employed in 
this study is per with the previous research (Zaerosa, 2016). The differences of anti-inflammatory 
activities between groups are assessed based on the measurements of paw edema volume, AUC0-6, and 
% anti-inflammatory effect.  
 
MATERIALS AND METHOD 
Materials 
Materials and tools used in this study include piroxicam (Indofarma), carrageenan (Lansida 
Group), oleic acid, tween 80, propylene glycol (Brataco), PVP (Cipta Kimia), NaCl 0.9% (Widatra 
Bhakti), HCl 37%, MgCl2 p.a, CaCl2 p.a, KCl p.a (Merck), male Wistar rats aged 2-3 months weighed 
150-250 gram, ultrasonicator (Elmasonic), dissolution test apparatus EDT 08Lx (Electrolab), vortex 
maxi mix II (Thermo Scientific), and spectrophotometer UV-1800 (Shimadzu). 
 
Methods 
Preparation of 1% PVP and 1% carrageenan  
One percent of PVP was prepared by adding 1 gram of PVP into aquadest up to 100 mL while 
1% carrageenan was made by diluting 50 mg of carrageenan into 0.9% NaCl up to 5 mL.   
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Preparation of piroxicam suspension  
Piroxicam suspension was made by diluting 200 mg of piroxicam into 1% PVP up to 100 mL 
with a final concentration of 2 mg/mL. The mixture was then stirred thoroughly to ensure 
homogenization. 
 
Preparation of SNEDDS piroxicam 
The SNEDDS piroxicam was prepared by loading the piroxicam into the SNEDDS carrier. The 
carrier was made from a mixture of oleic acid; tween 80; propylene glycol with a ratio of 4:33:13, 
respectively (Zaerosa, 2016). A 3.3 mL of tween 80 and 1.3 mL of propylene glycol were initially 
mixed and vortexed for 5 minutes. Afterward, 0.4 mL of oleic acid was added gradually and 
underwent an additional vortex for 10 minutes. The mixture was then sonicated at 45°C for 5 minutes 
before 70 mg of piroxicam was finally added into it. The final mixture was then ultrasonicated to 
ensure homogenization with a concentration equal to 70 mg/5mL. 
 
Orientation assay of carrageenan 
A 1% carrageenan was used as an irritant to induce paw edema in rats as described by 
(Mansouri et al., 2015). Eight rats were equally divided into two groups to undergo an orientation 
assay to ensure the carrageenan can induce paw edema in rats. The first group received 1.0 mL of 1% 
carrageenan whereas the second group received 1.0 mL  of 0.9% NaCl only, a solvent of carrageenan. 
The treatment for both groups was induced by sub-plantar injection in hind paws. The progress of paw 
edema was then monitored every 30 minutes for 6 hours. All procedures as to animal handling 
described herein follow the ethical clearance issued by the Animal Ethics Committee for Research of 
Universitas Ahmad Dahlan (registered number: 01170209). 
 
SNEDDS characterizations 
Percent transmittance (%) 
A 100 μl of the prepared SNEDDS was mixed with aquadest up to 5.0 mL and vortexed for 30 
seconds. The % transmittance was measured using an ultraviolet spectrophotometer at a wavelength of 
650 nm with aquadest as blank (Patel et al., 2011).  
 
Emulsification time 
The emulsification time was done using dissolution apparatus 2. As much as 500.0 mL of 
aquadest was initially conditioned as a medium in the dissolution apparatus 2 at 37℃. A 1.0 mL of the 
resulting SNEDDS was added into the medium while being constantly stirred at 100 rpm using the 
paddle. The emulsification time measurement was performed by observing the time needed from the 
moment SNEDDS was firstly introduced until the emulsion was completely formed in the medium.  
 
Anti-inflammatory activities assay 
All procedures described herein were approved by the Animal Ethics Committee for Research 
of Universitas Ahmad Dahlan with registration number 01170209. The dose of piroxicam for the 
animals was calculated according to the dose conversion factor from human to rats as described by the 
Laurence-Bacharach Method (Wilmana and Gunawan, 2007). The dose employed in this study was 
0.36 mg/200 g BW or 1.8 mg/kg BW. 
The anti-inflammatory effect was evaluated using paw edema rat assay by measuring the 
increase of mercury volume in rats that were previously induced by 1% carrageenan sub-plantar. 
Twenty male Wistar rats were equally divided into 4 groups and received treatments orally as follow: 
 
Negative Control I : received piroxicam suspension carrier orally  
Negative Control II : received SNEDDS carrier orally  
Positive Control  : received piroxicam suspension 1.8 mg/kg BW orally 
Treated Group : received SNEDDS piroxicam 1.8 mg/kg BW orally 
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All groups were given treatment with the same volume and after 5 minutes they were injected 
with 1% carrageenan sub-plantar in the hind paw to induce edema. Evaluation on edema volume 
alteration in the paw was done every 30 minutes for 6 hours using a plethysmometer. The edema 
volume was calculated using Equation 1 with baseline is defined as observation at 0 min. 
 
Edema volume = volume after treated − volume at baseline   …………………………………..(1) 
 
 
The Anti-inflammatory activity was assessed by measuring the Area under Curve (AUC) that 
was derived from the edema volume data. The AUC at 0 hour to 6 hours was calculated using the 
trapezoid method by Equation 2: 
 
AUC 0-6=   
X 0.5+X 0
2
× t0.5 − t0 +   
 X 1+X 0.5
2
× t1 − t0.5 ……………...+   
 X 6+X 5.5
2
× t6 − t5.5 ………………….…..(2  
 
Note: 
AUC 0-6  = area under curve at 0-6 hour 
x  = volume at hour  
t  = time 
 
Besides the above equation, the anti-inflammatory effect (referred to as %AE) was assessed by 
measuring the percentage of inflammation inhibition using Equation 3: 
 
% inflammation inhibition = 
(AUC 0-6 0 − (AUC 0-6 n
(AUC0-6 0
×100%   …………………………..(3)  
 
Note: 
(AUC 0-6)0  = AUC 0-6 average of negative control group (mm.hour) 
(AUC 0-6)n = AUC 0-6 of each rat that received treatment (mm.hour) 
 
Data Analysis 
Data presented herein were statistically analyzed by the Kruskal-Wallis test, Kolmogorov-
Smirnov test, and the Mann-Whitney test (p<0.05).  
 
RESULT AND DISCUSSION  
The SNEDDS carrier used for loading the piroxicam was a composition of oleic acid (8%), 
tween 80 (66%), and PG (26%) as described by (Zaerosa, 2016). Oleic acid serves as the oil phase 
while tween 80 and PG serve as the surfactant and co-surfactant, respectively.  
Before the main test, the freshly-prepared SNEDDS piroxicam was firstly characterized for 
percent transmittance and emulsification time. The percent transmittance defines the amount of light 
that can pass through material in percentage. This parameter allows to see the clarity of the prepared 
mixture that later can indicate whether the dispersed droplets are in the nano range (<100 nm) or not. 
A percent transmittance close to 100% is preferable for nanosized as the higher the value is, the 
smaller the size of dispersed droplets. In this study, the formed nanoemulsion was clear and 
transparent with the transmittance average of 99.16% ± 0.06 (n=3), suggesting that the droplets of 
resulting SNEDDS piroxicam are already nanosized. This result is in line with (Ke et al., 2016) and 
(Zaerosa, 2016).  
The emulsification time enables the evaluation in which the droplets quickly forming a 
homogenous mixture with mild stirring. Since the SNEDDS is a self-nanoemulsified carrier, this assay 
is of importance to take place. A good SNEDDS must feature immediate emulsification within 1 
minute as soon as it reaches GIT (Makadia et al., 2013). In the GIT, the spontaneous emulsification is 
further facilitated by a relatively low-energy agitation generated by peristaltic movement. Data 
obtained in this study exhibit an average time of emulsification at 44.82 ± 0.53 seconds (< 1 minute) 
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(n=3). This suggests that the prepared SNEDDS, once reaching the GIT, may be able to be emulsified 
spontaneously and meets the criteria of a good SNEDDS. This phenomenon has also been described 
by (Balakumar et al., 2013). Further, it is suggested that, regardless of tween as a surfactant, the 
accelerated emulsification time is also activated thanks to the presence of propylene glycol as a co-
surfactant by increasing the fluidity through penetration (Belhadj et al., 2013). 
Male Wistar strain rats aged 2-3 months with weights ranging from 150 to 250 grams were 
selected in this study. Males were preferred because it is relatively stable from hormonal imbalance. 
All animals used were acclimated by being kept in a standard laboratory condition for 7 days before 
the test to avoid unwanted variations caused by stress factors. All procedures as to animal handling 
were based on the ethical clearance issued by the Animal Ethics Committee for Research of 
Universitas Ahmad Dahlan (registered number: 01170209). 
After the characterization of SNEDDS had been established, a preliminary study was then 
performed before the anti-inflammatory assay by exposing the animals with carrageenan, an edema-
induced agent, in the hind paw to ensure that this irritant is indeed able to cause edema at the injection 
site. This preliminary was done by grouping 8 male Wistar rats into 2 groups equally. The first group 
received 0.1 mL of 1% carrageenan while the second group received 0.1 ml of the carrier (0.9% 
NaCl). The paw edema was observed every 30 minutes for 6 hours. The results demonstrated that only 
the group exposed with carrageenan experienced escalated paw edema volume while the second group 
which only received 0.9% NaCl had no edema at all (no edema volume escalation was observed as 
compared to the baseline). The difference between the groups is depicted in Figure 1. This confirms 




Figure 1. Paw edema volume alteration between groups from the preliminary test. All rats that 
received 0.1 mL of 1% carrageenan (white bar) show excessive paw swollen marked by 
increasing edema volume (in ml) after injection, while rats with 0.1 mL of 0.9% NaCl 
(black line), a solvent of carrageenan, had no edema throughout 6-hour observation 
(ρ<0.05) 
  
The anti-inflammatory activity was assessed by the carrageenan-induced paw edema method 
where the animals were injected using carrageenan sub-plantar in the hind paw to allow edema. As 
soon as the carrageenan was given, redness and swollen paw were immediately observed in the rats in 
each group. The edema was then measured for the volume of swelling produced in the paw as 
compared to the baseline. The paw edema volume was observed every 30 minutes for 6 hours using 
the plethysmometer. The lower the edema volume is, the greater the rats are protected from paw 
edema (Cong et al., 2015). The results in each group can be seen in Figure 2.  
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Figure 2. SNEDDS piroxicam group (solid black bar) exhibits the least paw edema volume while 
other groups were at a higher level. This indicates that the rats injected by SNEDDS 
piroxicam experienced the smallest swollen paw, suggesting that this group also had 
better protection from edema than the group injected with piroxicam suspension (white 
bar). a. significantly different from negative control I (ρ<0.05); b. significantly different 
from negative control II (ρ<0.05); c. significantly different from positive control 
(ρ<0.05) 
 
As depicted in Figure 2, negative control I and negative control II which received 1% PVP and 
SNEDDS carrier, respectively, showed a relatively high edema volume. This suggests that 1% PVP 
and SNEDDS carrier is least likely to have an anti-inflammatory effect which results in no protection 
from edema on the rats at all (it was observed during the study that the edema on the rats of these 
groups kept increasing even after a 6-hours observation was done). On the contrary, positive control 
which received piroxicam suspension and SNEDDS piroxicam group, showed lower edema volume as 
compared to negative control I and II with SNEDDS piroxicam group had the lowest paw edema 
volume (ρ<0.05). From the study, it was observed that the paw swelling on the rats in positive control 
started decreasing 4 hours after injection while in the SNEDDS piroxicam group was even quicker, the 
paw swelling started reducing 3 hours after injection (ρ<0.05). This result demonstrates that 
piroxicam-loaded SNEDDS has the greatest protection from paw edema on the rats between groups 
that may also suggest that SNEDDS piroxicam has better anti-inflammatory activity than the 
conventional piroxicam suspension.  
To further assess the anti-inflammatory activities of the SNEDDS piroxicam, the AUC0-6 value 
was calculated using the trapezoid method. The AUC0-6 was derived from the edema volume data and 
reflects the AUC value obtained from 0 to 6 hours data. This parameter is employed to further evaluate 
to what extent the anti-inflammatory activity in each group is. The smaller the value of AUC0-6, the 
greater the anti-inflammatory activity exerted by the compound (Sahlan et al., 2019). In other words, if 
the AUC0-6 value was relatively low, it indicates that the rats were prominently protected from severe 
edema as the swelling paw was gradually reduced over time thanks to the compound given. The result 
of the calculated AUC0-6 can be seen in Figure 3. 
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Figure 3.The average of AUC0-6 between the groups. The negative control I (striped bar) and 
negative control II (dotted bar) present a relatively high AUC0-6 value while positive 
control (white bar) and SNEDDS piroxicam group (solid black bar) show a markedly 
smaller value with the latter had the smallest. a. significantly different from negative 
control I (ρ<0.05); b. significantly different from negative control II (ρ<0.05); c. 
significantly different from positive control (ρ<0.05) 
 
As shown in Figure 3, the SNEDDS piroxicam group had the smallest value of AUC0-6 and is 
followed by positive control, negative control I, and negative control II in the second, third, and fourth 
place, respectively. This result suggests that the rats which received SNEDDS piroxicam were least 
affected by the paw edema (ρ<0.05). In addition, as the positive control had a higher value of AUC0-6 
than the SNEDDS piroxicam (ρ<0.05), this demonstrates that SNEDDS is likely to augment the anti-
inflammatory activity of the loaded piroxicam, thus leading to a better effect on the rats. 
To measure the anti-inflammatory activity, the AUC0-6 data can also be used to evaluate the 
percentage of anti-inflammatory effect (%AE) between groups using Equation 3. The %AE of the 
positive control group and SNEDDS piroxicam group were compared to further assess the anti-
inflammatory effect between these two groups. The %AE is displayed in Figure 4. 
 
   
 
Figure 4. A comparison of %AE between positive control group (white bar) and SNEDDS 
piroxicam group (black bar). This graph reveals that the rats given with SNEDDS 
piroxicam received over 3 times higher anti-inflammatory effects than the piroxicam 
suspension group did. *Significantly different from the positive control group (ρ<0.05) 
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Based on Figure 4, the SNEDDS piroxicam group exhibits a considerably higher %AE than that 
of the positive control with 42.5±3.4 % and 11.8±2.6%, respectively. The gap between these groups is 
significantly huge (over 30%) (ρ<0.05), meaning that the SNEDDS piroxicam managed to alleviate 
the swollen paw on the rats to a greater extent compared to those that received piroxicam suspension 
only. Based on this result, the rats with SNEDDS piroxicam were most likely to experience an 
enhanced anti-inflammatory effect; therefore, the %AE is higher than the ones with piroxicam without 
SNEDDS. 
A better anti-inflammatory activity of SNEDDS piroxicam over piroxicam suspension as 
demonstrated in this study may be explained by several factors: first, the SNEDDS may improve 
piroxicam solubility via spontaneous emulsification in the GI fluid. Within the GIT, the SNEDDS may 
promote immediate nanoemulsion formation, where the piroxicam is presented in the solubilized state 
that leads to dissolution rate enhancement (Belhadj et al., 2013). Second, nanosized emulsion droplets 
produced by SNEDDS may significantly increase the surface area needed for enhanced drug 
absorption within the intestine, thereby allowing better bioavailability (Kanwal et al., 2019). Third, the 
use of lipid in the SNEDDS is thought to also promote the absorption rate via the intrinsic lipid 
pathway (Mirza et al., 2010). Fourth, by loading into SNEDDS, the piroxicam tends to be well-
protected from liver-induced first-pass-elimination preventing the early drug degradation. In such 
conditions, the ratio of active compound that can be presented/ available in systemic circulation may 
be raised, thus optimum therapeutic concentration can be achieved, therefore enabling high systemic 
bioavailability (Motawea et al., 2017). These combined factors are likely to cause an improvement of 
anti-inflammatory effect on SNEDDS piroxicam as compared to piroxicam in conventional suspension 
form. However, since this study only describes the anti-inflammatory effect as evaluated via paw 
edema volume, AUC0-6 and %AE, further studies such as in vivo and pharmacokinetic studies are still 
needed for improvement and establishing the findings in more depth.  
 
CONCLUSION 
SNEDDS significantly enhances the anti-inflammatory activity of loaded piroxicam compared 
to that of piroxicam suspension. The rats treated with SNEDDS piroxicam demonstrated better 
protection from paw edema than other groups, suggesting SNEDDS is a promising approach for the 
delivery of water-insoluble drugs.  
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